Insider buying last 90 days
No open-market insider purchases were filed for IOVA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every IOVA insider filing, plotted on the chart in Gekko.Open IOVA in Gekko
NASDAQ: IOVA
Iovance Biotherapeutics (IOVA) Stock Analysis & Forecast
Sep 28 close
$10.99−0.01 (−0.1%)
Gekko Brief
AI summaryIovance Biotherapeutics reached a new 52-week high of $10.98 this week, with shares rising almost 6% on a resumed Goldman Sachs coverage rating of "buy" and a $15.00 price target from analyst Andrea Newkirk, citing strong Q2 performance of Amtagvi and its increasing use as a second-line melanoma treatment. The stock has extended a run described as six straight green days, up 26%, adding to its recent momentum.
IOVA closed at $10.99, essentially flat on the day, and sits above both its 50-day average of $7.53 and its 200-day average of $4.49, with the shorter average above the longer one, indicating an established uptrend. The GekkoIndex reads 47, placing the stock in the Neutral zone. Price stands 42.2% above the Gekko Fair Value of $7.73.
The next earnings report is set for 5 November 2026, 37 days out and beyond a typical 20-trading-day holding window; the prior print on 6 August 2026 showed a loss of $0.11 per share against a $0.17 estimate and was followed by a 46.1% reaction. No insider, Congress or unusual options activity appears in the current windows. Consensus among 8 firms shows 6 buy and 2 hold ratings, with a consensus target of $10.70. Seasonality over 5 years shows an average 20-day return of 0.4%, positive in 3 of those years.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Iovance Biotherapeutics price vs fair value
Close $10.99200-day averageGekko Fair Value $7.73
Iovance Biotherapeutics quick facts
- Market cap
- $4.91B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$0.69
- Revenue, TTM
- $325.0M
- Profit margin
- -89.1%
- Dividend yield
- —
- Beta
- 0.83
- Volume
- 12.21M avg 13.80M
- 1-year return
- +444.1%
- Typical daily move
- ±5.6%
- Typical 20-day move
- ±14.2%
- 50-day average
- $7.53
- 200-day average
- $4.49
- Next earnings
- Nov 5
- Shares outstanding
- 453.0M
Iovance Biotherapeutics swing-trade checklist
Iovance Biotherapeutics scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $10.99 is above the 50-day ($7.53) and 200-day ($4.49) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
47, Neutral
Reading 47 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
42.2% above
Price is 42.2% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 37 days
Next report Nov 5, 2026, 37 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+0.4% on average
From this point in the calendar, the next 20 trading days averaged +0.4% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Iovance Biotherapeutics stock chart and price history
Iovance Biotherapeutics closed at $10.99 on Sep 28, 2026, +444.1% over the past year, inside a 52-week range of $1.76 to $11.17.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +33.1%
- 3 months
- +161.0%
- 6 months
- +213.1%
- 1 year
- +444.1%
The full IOVA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open IOVA in Gekko
Follow Iovance Biotherapeutics through every session
Put IOVA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track IOVA in GekkoFree for 7 days. No credit card required.
About Iovance Biotherapeutics
Iovance Biotherapeutics develops experimental cancer treatments built around harnessing a patient's own immune defenses to fight tumors from within. The company has not yet reached commercial sales, remaining in clinical development, and its research is anchored by a lead candidate called lifileucel, which is being studied in people with advanced melanoma as well as those facing cervical cancer that has returned, spread, or persisted after other treatment. A second compound, LN-145, is being tested in patients dealing with head and neck squamous cell carcinoma that has come back or spread, and altogether the company has six separate Phase 2 studies underway.
Rather than earning revenue from finished products, Iovance advances its pipeline through collaborations and licensing deals with outside research and treatment centers. Its partners include Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG, reflecting a reliance on shared scientific and clinical resources rather than a customer base in the traditional sense.
The company traces back to 2007 and operated for years under the name Lion Biotechnologies before switching to its current identity in June 2017. It runs its operations from San Carlos, California, and its shares trade on the NASDAQ under the ticker IOVA.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- iovance.com
Iovance Biotherapeutics GekkoIndex: the smart money zone
Iovance Biotherapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 47, in the Neutral zone, up 1.7 points over five sessions.
47Neutral
Up 1.7 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 82 | +1.6% | +3.9% |
| Accumulation | 222 | +2.0% | +3.9% |
| Neutral (current zone) | 325 | +0.6% | +5.3% |
| Distribution | 31 | +3.1% | +3.9% |
| Selling | 12 | −1.3% | −13.8% |
Average IOVA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the IOVA price, zone by zone.Track IOVA in Gekko
Is Iovance Biotherapeutics stock overvalued? Gekko Fair Value
Iovance Biotherapeutics trades 42.2% above Gekko Fair Value of $7.73, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Iovance Biotherapeutics shares are worth, recalculated every trading day.
$7.73
Gekko Fair Value, Sep 29, 2026
42.2% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open IOVA in Gekko
Iovance Biotherapeutics insider and Congress trading
No open-market insider purchases were filed for Iovance Biotherapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in IOVA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for IOVA, plotted on the chart in Gekko.Open IOVA in Gekko
Buybacks
Iovance Biotherapeutics has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $861K
- As a share of market cap
- 0.02%
From company filings.
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold IOVA.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Iovance Biotherapeutics earnings: next date and track record
Iovance Biotherapeutics reports on Nov 5, 2026 (37 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 5, 2026
37 days away
- EPS estimate
- −$0.12
- Revenue estimate
- $110.8M
4 of 8reports beat the EPS estimate
±26.6%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- Iovance reported record Q2 2026 revenue of $99.3 million, exceeding guidance, with all-time high gross margin of 56%. Commercial Amtagvi demand hit record levels with 50+ patients treated monthly across expanding authorized treatment centers. Pipeline advanced with FDA Fast Track designation for sarcoma program (SAR-201) showing 50% ORR, and endometrial cancer trial showing 40% confirmed ORR. R&D expenses declined for fourth consecutive quarter.
- Guidance
- Management maintains peak U.S. sales assumption of $1B+ for Amtagvi and Proleukin in advanced melanoma alone. Q3 performance described as 'very strong'; full year guidance update expected during Q3. sBLA filing for non-small cell lung cancer targeted for 2027.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.11 est −$0.17 | $99.31M est $87.83M | +46.1% |
| May 7, 2026 | −$0.19 est −$0.15 | $71.43M est $77.84M | −11.5% |
| Feb 24, 2026 | −$0.18 est −$0.18 | $86.71M est $80.71M | +32.5% |
| Nov 6, 2025 | −$0.25 est −$0.26 | $67.46M est $82.17M | +27.1% |
| Aug 7, 2025 | −$0.33 est −$0.29 | $59.95M est $78.32M | −18.2% |
| May 8, 2025 | −$0.36 est −$0.25 | $49.32M est $82.37M | −44.1% |
| Feb 27, 2025 | −$0.26 est −$0.27 | $73.69M est $72.17M | −20.7% |
| Nov 7, 2024 | −$0.28 est −$0.30 | $58.55M est $71.57M | −12.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Iovance Biotherapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Iovance Biotherapeutics is $10.70, −2.6% from the last close, from 8 firms rating the stock in the last 90 days.
$10.70consensus 12-month target, −2.6% from the last close
Now $10.99Avg $10.70
Low $6High $15
Each firm’s latest rating in the last 90 days: 8 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 24 | Goldman Sachs | $15 | +36.5% |
| Sep 17 | Barclays | $15 | +36.5% |
| Aug 25 | TD Cowen | $10 | −9.0% |
| Aug 25 | TD Cowen | $10 | −9.0% |
| Aug 20 | UBS | $7 | −36.3% |
+5.3%average 20-day move after past Neutral readings
+0.4%average move over the next 20 trading days in the last 5 years
±5.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Iovance Biotherapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Sep 26, Iovance Biotherapeutics averaged +0.4% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.7% | 3 of 5 |
| Next 10 trading days | −2.0% | 2 of 5 |
| Next 15 trading days | −2.8% | 3 of 5 |
| Next 20 trading days | +0.4% | 3 of 5 |
| Next 30 trading days | +4.5% | 2 of 5 |
For scale, IOVA’s typical 20-trading-day move in either direction is about 14.2%.
Iovance Biotherapeutics market cap and key statistics
Iovance Biotherapeutics’s market cap is $4.91B and revenue of $325.0M over the last twelve months.
Valuation
- Market cap
- $4.91B
- EPS, TTM
- −$0.69
- Gekko Fair Value
- $7.73
Trading
- Volume
- 12.21M
- Avg volume, 20 days
- 13.80M
- 52-week high
- $11.17
- 52-week low
- $1.76
- Shares outstanding
- 453.0M
Financials
- Revenue, TTM
- $325.0M
- Profit margin
- -89.1%
- Return on equity
- -40.4%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.83
- Typical daily move
- ±5.6%
- Typical 20-day move
- ±14.2%
Iovance Biotherapeutics stock news this week
Coverage of Iovance Biotherapeutics this week reads positive: 6 positive, 1 neutral and 0 negative headlines.
- Iovance Biotherapeutics stock hits 52-week high at 10.98 USDInvesting.com, Sep 25
- Why Iovance Biotherapeutics Stock Was on Fire TodayThe Globe and Mail, Sep 25
- Iovance Biotherapeutics Price Target Announced at $15.00/Share by Goldman SachsMoomoo, Sep 25
- Iovance Biotherapeutics, Inc. (IOVA) Options Chain - Yahoo FinanceYahoo! Finance Canada, Sep 23
- Iovance Biotherapeutics, Inc. (IOVA) stock price, news, quote and historyYahoo Finance UK, Sep 22
- Iovance Biotherapeutics, Inc. (IOVA) Stock Price, News, Quote & HistoryYahoo! Finance Canada, Sep 22
Iovance Biotherapeutics peers
Iovance Biotherapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
Iovance Biotherapeutics stock FAQ
What is Iovance Biotherapeutics’s market cap?
Iovance Biotherapeutics’s market cap is $4.91B at the Sep 28, 2026 close of $10.99, with 453.0M shares outstanding.
What is the Iovance Biotherapeutics stock forecast?
The consensus analyst 12-month price target for Iovance Biotherapeutics is $10.70, −2.6% from the last close. Of the 8 firms that rated the stock in the last 90 days, 6 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Iovance Biotherapeutics stock overvalued or undervalued?
On Gekko’s estimate Iovance Biotherapeutics is overvalued: the Sep 28, 2026 close of $10.99 is 42.2% above Gekko Fair Value of $7.73. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Iovance Biotherapeutics report earnings next?
Iovance Biotherapeutics is expected to report on Nov 5, 2026 (37 days away). Analysts expect earnings of −$0.12 per share on revenue of $110.8M. Iovance Biotherapeutics beat the earnings estimate in 4 of its last 8 reports, moving 26.6% on average across the report.
What is Iovance Biotherapeutics’s 52-week high and low?
Iovance Biotherapeutics’s 52-week high is $11.17 and its 52-week low is $1.76; it closed at $10.99 on Sep 28, 2026, +444.1% over the past year. Over the last five years the shares peaked at $27.96 on Oct 14, 2021.
Is Iovance Biotherapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Iovance Biotherapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.